The life sciences industry is undergoing a fundamental change in its business model. The shifts from blockbuster drug to precision medicine and from volume-based to performance-based models have disrupted the life sciences ecosystem. The cost of clinical trials is continuing to climb and in order to move away from this high-cost R&D model as well as to enable closer engagement with patients. Nitish Mittal and Kanika Gupta at Everest Group explain why pharma and research companies are turning to digital technologies to transform clinical development.
Read more in IBI media
